Ciaran Murray Sells 2,677 Shares of Icon (NASDAQ:ICLR) Stock

Icon Plc (NASDAQ:ICLR) Director Ciaran Murray sold 2,677 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total transaction of $439,804.33. Following the completion of the sale, the director directly owned 20,452 shares of the company’s stock, valued at $3,360,059.08. This trade represents a 11.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Icon Stock Performance

Shares of ICLR opened at $167.48 on Friday. The company’s 50 day moving average price is $162.22 and its 200 day moving average price is $134.04. Icon Plc has a 52 week low of $66.57 and a 52 week high of $203.91. The company has a market capitalization of $12.82 billion, a PE ratio of 39.31, a PEG ratio of 6.93 and a beta of 1.21. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.95 and a current ratio of 0.95.

Icon (NASDAQ:ICLR) last released its quarterly earnings data on Thursday, July 30th. The medical research company reported $2.56 earnings per share for the quarter, beating the consensus estimate of $2.55 by $0.01. Icon had a net margin of 3.99% and a return on equity of 8.02%. The firm had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2 billion. During the same quarter in the prior year, the business earned $3.26 EPS. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. Research analysts expect that Icon Plc will post 9.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Icon

A number of large investors have recently bought and sold shares of the business. Jennison Associates LLC acquired a new position in Icon during the 4th quarter worth $123,542,000. Calamos Advisors LLC acquired a new stake in shares of Icon in the fourth quarter valued at about $4,829,000. OVERSEA CHINESE BANKING Corp Ltd acquired a new stake in shares of Icon in the fourth quarter valued at about $2,960,000. Hudson Edge Investment Partners Inc. increased its stake in shares of Icon by 29.7% in the fourth quarter. Hudson Edge Investment Partners Inc. now owns 260,449 shares of the medical research company’s stock worth $47,459,000 after purchasing an additional 59,710 shares during the period. Finally, Fisher Funds Management LTD increased its stake in shares of Icon by 19.0% in the fourth quarter. Fisher Funds Management LTD now owns 513,102 shares of the medical research company’s stock worth $93,208,000 after purchasing an additional 82,019 shares during the period. 95.61% of the stock is currently owned by institutional investors.

Trending Headlines about Icon

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Icon’s latest quarterly results modestly exceeded expectations: adjusted EPS was $2.56 versus the $2.55 consensus, while revenue of $2.06 billion topped estimates of $2.00 billion. Revenue also rose 2.3% year over year, indicating continued demand for its outsourced clinical-research services.
• Positive Sentiment: Analyst support remains a potential catalyst. BMO Capital Markets raised its price target to $187, Mizuho lifted its target to $190, and William Blair upgraded the stock to “strong buy.” The broader analyst consensus is “Hold,” with an average target of $170.40. Analyst coverage article
• Positive Sentiment: Institutional ownership is high at 95.61%, and several investment firms recently initiated or increased positions in ICLR. The stock is also trading above its 50-day and 200-day moving averages, reflecting favorable recent momentum.
• Neutral Sentiment: CEO Barry Balfe, CFO Nigel Clerkin and several directors sold shares totaling roughly $1.6 million at prices near $164.07–$164.29. The filings state that the sales were made to cover tax-withholding obligations connected with vested equity awards, and the insiders retained shares afterward, reducing the negative signal. Icon insider sales article
• Negative Sentiment: Although revenue beat estimates, quarterly EPS fell from $3.26 in the prior-year period, highlighting earnings pressure. ICLR also trades at a relatively demanding valuation, with a price-to-earnings ratio near 39 and a PEG ratio above 6, leaving the stock vulnerable if growth or guidance weakens.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Barclays increased their price objective on Icon from $160.00 to $175.00 and gave the stock an “equal weight” rating in a report on Thursday, June 25th. Leerink Partners set a $145.00 target price on Icon in a research report on Thursday, May 28th. Truist Financial reaffirmed a “buy” rating and set a $209.00 price target (up from $207.00) on shares of Icon in a research note on Friday, July 31st. JPMorgan Chase & Co. lifted their price target on Icon from $130.00 to $155.00 and gave the company a “neutral” rating in a report on Thursday, June 25th. Finally, DA Davidson set a $164.00 price target on Icon in a research note on Monday, June 1st. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $170.40.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.